前列腺癌：更好的 VISTAs 前景？免疫疗法的潜力和陷阱。
Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy.
机构信息
Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive 13N240, Bethesda, Maryland 20892, USA.
出版信息
Nat Rev Urol. 2017 Aug;14(8):455-456. doi: 10.1038/nrurol.2017.75. Epub 2017 May 23.
Abstract
Despite a rapid increase in the use of anticancer immunotherapy, our understanding of the mechanisms of action and the patients’ responses remains limited. The discovery of immune inhibitory markers in the tumour microenvironment following immunotherapy should improve our understanding and might enable us to better apply combination therapies.
摘要
尽管抗癌免疫疗法的应用迅速增加，但我们对其作用机制和患者反应的理解仍然有限。免疫疗法后在肿瘤微环境中发现的免疫抑制标志物应该会增进我们的了解，并可能使我们能够更好地应用联合疗法。
相似文献
1
Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy.前列腺癌：更好的 VISTAs 前景？免疫疗法的潜力和陷阱。
Nat Rev Urol. 2017 Aug;14(8):455-456. doi: 10.1038/nrurol.2017.75. Epub 2017 May 23.
2
Therapeutic prostate cancer vaccines: a review of the latest developments.治疗性前列腺癌疫苗：最新进展综述
Curr Opin Investig Drugs. 2008 Dec;9(12):1296-301.
3
Clinical development of immunotherapy for prostate cancer.前列腺癌免疫疗法的临床开发
Int J Urol. 2017 Sep;24(9):675-680. doi: 10.1111/iju.13397. Epub 2017 Jun 21.
4
Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.免疫检查点 B7-H3 蛋白表达与前列腺癌的不良预后和雄激素受体状态相关。
Prostate. 2021 Sep;81(12):838-848. doi: 10.1002/pros.24180. Epub 2021 Jun 14.
5
Prostate cancer: any room left for immunotherapies?前列腺癌：免疫疗法还有空间吗？
Immunotherapy. 2019 Feb;11(2):69-74. doi: 10.2217/imt-2018-0159.
6
The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.肿瘤微环境与前列腺癌和膀胱癌的免疫治疗。
Urol Clin North Am. 2020 Nov;47(4S):e17-e54. doi: 10.1016/j.ucl.2020.10.005.
7
B7-H3: a robust target for immunotherapy in prostate cancer.B7-H3：前列腺癌免疫治疗的可靠靶点。
Trends Cancer. 2024 Jul;10(7):584-587. doi: 10.1016/j.trecan.2024.05.003. Epub 2024 Jun 4.
8
Current perspectives in prostate cancer vaccines.当前前列腺癌疫苗的研究现状。
Anticancer Agents Med Chem. 2009 Dec;9(10):1052-7. doi: 10.2174/187152009789735062.
9
Immunotherapy for Prostate Cancer.前列腺癌的免疫治疗。
Cold Spring Harb Perspect Med. 2019 May 1;9(5):a030627. doi: 10.1101/cshperspect.a030627.
10
The new aspects of immunotherapy in prostate cancer.前列腺癌免疫治疗的新进展
Cancer Immunol Immunother. 2012 Dec;61(12):2375-6. doi: 10.1007/s00262-012-1309-2. Epub 2012 Jun 27.
引用本文的文献
1
SNAP25 is a potential prognostic biomarker for prostate cancer.SNAP25是前列腺癌一种潜在的预后生物标志物。
Cancer Cell Int. 2022 Apr 7;22(1):144. doi: 10.1186/s12935-022-02558-2.
2
LPAR1, Correlated With Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer.与免疫浸润相关的LPAR1是前列腺癌中一种潜在的预后生物标志物。
Front Oncol. 2020 Jun 10;10:846. doi: 10.3389/fonc.2020.00846. eCollection 2020.
3
Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.免疫检查点在前列腺癌靶向免疫治疗中的临床应用。
Cell Mol Life Sci. 2020 Oct;77(19):3693-3710. doi: 10.1007/s00018-020-03459-1. Epub 2020 Jan 31.
4
Potentiating prostate cancer immunotherapy with oncolytic viruses.溶瘤病毒增强前列腺癌免疫治疗。
Nat Rev Urol. 2018 Apr;15(4):235-250. doi: 10.1038/nrurol.2018.10. Epub 2018 Feb 13.
本文引用的文献
1
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.VISTA是一种抑制性免疫检查点，在前列腺癌患者接受伊匹单抗治疗后会升高。
Nat Med. 2017 May;23(5):551-555. doi: 10.1038/nm.4308. Epub 2017 Mar 27.
2
Immunoregulatory functions of VISTA.VISTA的免疫调节功能。
Immunol Rev. 2017 Mar;276(1):66-79. doi: 10.1111/imr.12525.
3
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.随机、双盲、III 期试验：依匹单抗对比安慰剂在无症状或症状轻微的转移性化疗初治去势抵抗性前列腺癌患者中的应用。
J Clin Oncol. 2017 Jan;35(1):40-47. doi: 10.1200/JCO.2016.69.1584. Epub 2016 Oct 31.
4
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.肿瘤干扰素信号传导调控针对免疫检查点阻断的多基因抗性程序。
Cell. 2016 Dec 1;167(6):1540-1554.e12. doi: 10.1016/j.cell.2016.11.022.
5
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.抗程序性死亡蛋白1（PD-1）活性在恩杂鲁胺耐药前列腺癌中的早期证据。
Oncotarget. 2016 Aug 16;7(33):52810-52817. doi: 10.18632/oncotarget.10547.
6
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
7
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.术前使用西妥昔单抗治疗局限性前列腺癌后，活化淋巴细胞募集至肿瘤微环境。
J Natl Cancer Inst. 2014 Sep 24;106(11). doi: 10.1093/jnci/dju268. Print 2014 Nov.
8
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.依匹木单抗联合放疗对比安慰剂用于多西他赛化疗后进展的转移性去势抵抗性前列腺癌患者（CA184-043）：一项多中心、随机、双盲、III 期临床试验。
Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13.
9
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
Zotero 插件